Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intracellular pharmacokinetics of decitabine in adults with AML or MDS
NL-OMON46533Phase 4Withdrawn
- Sponsor
- University Medical Center Groningen
- Start
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by University Medical Center Groningen. Primary endpoints: Intracellular concentrations of decitabine, Intracellular concentrations of decitabine phosphates and 2 more. Planned start Apr 2018; status: withdrawn.
02
Drugs
decitabine
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON46533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46533.